DEXMEDETOMIDINE OR MEDETOMIDINE FOR USE IN THE TREATMENT OF SEPARATION ANXIETY IN DOGS Russian patent published in 2021 - IPC A61K31/4174 A61K47/20 A61K47/38 A61P25/20 

FIELD: pharmaceutics.

SUBSTANCE: group of inventions relates to the field of pharmaceutics, namely to a method for the treatment of separation anxiety in dogs and to the use of dexmedetomidine or its pharmaceutically acceptable salt as a single active ingredient in the form of oromucosal semi-solid gel for the treatment of separation anxiety in dogs. The method includes the injection to an animal of dexmedetomidine or its pharmaceutically acceptable salt as a single active ingredient in the form of semi-solid gel for oromucosal use at a dose from 100 mkg/m² to 150 mkg/m², wherein gel contains from 0.005 to 0.05% wt./wt. of dexmedetomidine or its pharmaceutically acceptable salt.

EFFECT: group of inventions provides for the creation of effective medicamental non-sedative treatment of separation anxiety in dogs, when using dexmedetomidine or its pharmaceutically acceptable salt as a single active ingredient in the form of oromucosal semi-solid gel having quick start of action, relatively simple injection to be performed by the dog’s owner, and effective mitigation of symptoms of separation anxiety for at least 8 hours.

11 cl, 2 tbl, 7 ex